Top Tech Companies in Boston, MA (4,869)

Strong Revenue Growth: Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.

Market Expansion: U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.

Customer Loyalty & Retention: Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.

Resilient & Sustainable Growth: Revenue has risen at a steady mid- to high-single-digit pace—FY2025 grew 8.3% on a normalized basis, with FY2026 Q1 and Q2 up 7.7% and 7.3% respectively, alongside 3.8% active-customer growth. Management also raised its FY2026 net sales outlook, pointing to continued expansion.

Customer Loyalty & Retention: Autoship sales increased 9.3% in Q2 FY2026 to about $2.82 billion and represented 84.6% of total sales, supporting predictable, repeat purchasing. Sales per active customer also edged up to $602, indicating deepening engagement.

Profitability: Adjusted EBITDA climbed 23.7% in Q2 FY2026 to $226.7 million with a 6.8% margin, and net income rose year over year. These gains indicate improving operating earnings alongside growth.

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Strong Revenue Growth: Global revenue increased to $60.2B in FY2026, with growth accelerating versus the prior year and all major service lines expanding. Asia Pacific and the Americas contributed most, though expansion was not uniform across regions.

Innovation-Driven Growth: Significant, multi‑billion investments are scaling AI and technology capabilities, alongside large‑scale AI upskilling across the workforce. Initiatives such as AI‑native assurance tools and the PwC One platform indicate a push to embed tech-enabled delivery.

Product Line Growth: New and expanded offerings in technology, consulting, strategy, and tax are being built through acquisitions and strategic investments. Within the latest year, Tax and Legal led growth, with Advisory and Assurance also advancing.

Strong Revenue Growth: Reporting indicates revenue increased in successive years, with UK results showing clear year-over-year gains and the parent highlighting category increases linked to the business. This pattern points to solid top-line momentum across core operations.

Profitability: Operating and post-tax profit improved materially, at times outpacing revenue growth. Such margin expansion suggests enhanced earning efficiency and disciplined execution.

Market Expansion: Customer reach advanced to a major UK milestone while U.S. distribution broadened through accelerated agent activity and additional channels. New insurer partnerships and digital launches further extend access to buyers.

Strong Revenue Growth: Reported bookings and subscription revenue more than doubled in 2025, indicating accelerating commercial scale. Membership expanded into the millions by mid-2026, reinforcing top-line momentum.

Market Expansion: International membership surged and the company broadened distribution into retail, wholesale, and enterprise channels, extending growth beyond direct-to-consumer. Positioning widened from elite athletes to everyday health, sleep, and longevity use cases.

Investor Backing & Capital Strength: A substantial Series G at a markedly higher valuation brought significant capital from institutional and strategic investors. The raise supported planned headcount expansion and continued product development.

Strong Revenue Growth: ARR is reported to have more than tripled between 2021 and 2025 while profitability improved. AI-related ARR also rose from $20 million in Q1 2025 to $109 million in Q1 2026, reinforcing momentum.

Market Expansion: Reported enterprise customers grew from 1,200+ in 2024 to 1,500+ in 2025, and platform reach expanded from 15 million to 25 million endpoints/employees. International moves, including plans for Japan and South America, indicate continued geographic expansion.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3 billion valuation in 2025 signals strong external confidence. This transaction follows years of scaling and provides capital support for the next phase.

Strong Revenue Growth: Reported ARR surpassed $200 million in June 2026 with five consecutive years of 100% year-over-year growth, indicating rapid scaling. Adoption breadth, including claims of powering one in six U.S. apartments, reinforces the commercial momentum behind that trajectory.

Investor Backing & Capital Strength: A $350 million round in September 2026 at a $4 billion valuation, with major existing investors participating alongside Ontario Teachers’ Pension Plan, underscores substantial access to capital. This financing signals strong confidence to fund continued product development and go-to-market expansion.

Market Expansion: Reach reportedly grew from about one in twelve U.S. apartments in 2024 to one in six in 2026, alongside plans for a second engineering hub in San Francisco. The company is also expanding from leasing into broader property-management workflows and healthcare administration.

Investor Backing & Capital Strength: A $17 million investment in May 2026 from Enlightened Hospitality Investments signals strong financial support for scaling product and market reach. A documented multi-round funding history further reinforces access to capital for growth.

Strategic Partnerships: A global partnership with Shake Shack and a large-scale rollout at JD Group highlight the ability to win and expand enterprise relationships. Placement as a Workday Ventures portfolio company underscores ecosystem alignment that can accelerate distribution.

Market Expansion: Reported additions of over 700,000 hospitality users in 2025 and new international deployments point to widening geographic and vertical reach. Enterprise wins across retail, hospitality, transportation, and healthcare indicate momentum beyond a single sector.

Strong Revenue Growth: Revenue is described as up 54% over two years, with inclusion on the Inc. 5000 and the Financial Times’ Americas’ Fastest-Growing Companies list reinforcing multi‑year expansion. These signals point to sustained commercial momentum.

Strong Hiring & Retention: Headcount reportedly expanded from about 35 in 2021 to roughly 160–175 in 2026, alongside a 48% year‑over‑year hiring increase, indicating scaled delivery capacity. Active recruitment across engineering and operations further suggests continued team growth.

Market Expansion: The company extended its footprint into EMEA (2023) and APAC (2026), beginning with hires in Australia. International hiring indicates access to new markets and service opportunities.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Strong Revenue Growth: Revenue is rising steadily, including 11% year-over-year growth to $192.8 million in Q2 2026 and 7% growth for full-year 2025. The step-up from 6% growth in Q1 2026 to 11% in Q2 indicates accelerating momentum.

Profitability: Adjusted EBITDA increased 30% year over year in Q2 2026 as margin expanded from 34% to 37%, signaling operating leverage. Net income also improved to $19.4 million from $11.1 million year over year in that quarter.

Healthy Cash Flow: Guidance points to free-cash-flow growth in the high-40% range for 2026 alongside adjusted EBITDA growth of more than 20%. Operating cash flow reached $57.4 million in Q2 2026.

Strong Revenue Growth: Annual recurring revenue is described as rising to $218M in 2025 with 23% year-over-year growth, indicating accelerating top-line momentum versus 2024.

Profitability: Full-year group-level profitability in 2025 is reported, suggesting growth is accompanied by improved financial sustainability.

Product Line Growth: Mirakl Connect and Mirakl Ads are cited as scaling quickly, adding new recurring revenue and ecosystem activity beyond the core marketplace platform.

Strong Revenue Growth: Revenue is advancing at double-digit rates across multiple periods, with FY2026 revenue rising 19% to about $2.02B and fiscal Q1 FY2027 revenue up 16% to $555M. ARR also increased 17% in the latest quarter, reinforcing breadth of growth in a subscription model.

Healthy Cash Flow: Cash generation is robust, including approximately $529M in free cash flow for FY2026 and operating cash flow of roughly $306M in Q1 FY2027. These indicators suggest expansion is supported by solid liquidity rather than heavy cash burn.

Product Line Growth: Log management is scaling rapidly, with annualized consumption reaching about $200M in Q1 FY2027 and growing at more than 100% year over year. Investment in AI-powered operations and platform capabilities is extending the growth runway.

Product Line Growth: Product expansion into industrial robotics with kilo alongside ongoing consumer variants (e.g., Star Wars-inspired gitamini) and feature updates points to a broader offering. This widens the use cases from personal cargo robots to workplace and industrial material handling.

Market Expansion: A visible pivot toward B2B use cases, including planned factory deployments and stated fleet rollouts with several Fortune Global 500 companies, indicates broader commercial reach. The Disney collaboration adds an additional retail channel and audience for consumer products.

Innovation-Driven Growth: Continued technology investment—such as hybrid-navigation AI, Forward Following, and Trips—shows an active R&D agenda. A large human-motion dataset and iterative capability releases suggest efforts to improve commercial usefulness in dynamic environments.

Strong Hiring & Retention: Headcount and hiring momentum are evident, with third-party estimates showing growth from roughly the mid‑teens of thousands in 2024 to 20,000+ by 2025–2026 and plans to hire thousands, alongside new capacity such as the Hyderabad operations center. This suggests the company is scaling delivery and talent depth across geographies.

Innovation-Driven Growth: The firm has expanded into AI and digital offerings, including its ZAIDYN platform, acquisitions like Digital Additive and Torrent Consulting, and launches such as Myelo developed with the International Myeloma Foundation. These moves indicate investment beyond traditional consulting into scalable, tech‑enabled services.

Market Expansion: A dedicated mid‑cap pharmaceutical vertical and the opening of an operations center in Hyderabad point to deliberate expansion in target segments and delivery footprint. These steps signal efforts to broaden served markets and strengthen execution capacity.

Profitability: Operating and net income remained positive even as revenue softened in recent quarters. This indicates an earnings base that is holding up during a period of slower demand.

Healthy Cash Flow: Free cash flow stayed positive with meaningful generation quarter to quarter, and guidance points to continued cash production. Liquidity is reinforced by a sizable balance of cash, cash equivalents, and government securities.

Future-Ready Strategy: Management is concentrating investment on the Command Platform, detection and response, exposure management, and AI-enabled security operations. This refocus aims to position the portfolio for a return to growth once the transition progresses.

Strong Revenue Growth: Recent results show revenue up 27.2% year over year in Q2 2026, with full-year 2025 revenue rising 26.6% to $623 million. Management also raised its 2026 growth outlook, reinforcing the trajectory.

Market Expansion: Client additions of 200+ across 45 countries in both Q1 and Q2 2026 and growth beyond education into travel, healthcare, and B2B indicate a broadening footprint. Education revenue outside core markets growing 30%+ further supports geographic expansion.

Profitability: Adjusted EBITDA increased 44.5% in Q2 2026 with margin expansion, and full-year 2025 reported positive net income. These trends suggest improving earnings power alongside scale.

Strong Revenue Growth: Revenue is considered to be expanding strongly over multiple years, with recent quarters delivering double-digit increases and an upgraded full‑year outlook. Underlying demand also appears robust as gross booking volume and new signed enterprise bookings have risen sharply.

Market Expansion: The customer base has grown to more than 12,500 with record new signed enterprise bookings and expansion into regions such as Europe and India. Added offerings like meetings and events further broaden the company’s reach across segments and geographies.

Healthy Cash Flow: Operating cash flow and free cash flow turned positive for the latest full fiscal year, and the company reported positive cash generation in a recent quarter. This suggests improving operating leverage even as the business scales.

Strong Revenue Growth: Square’s segment revenue increased 10% in 2025 and rose 16% year over year in Q2 2026, pointing to renewed topline momentum. These gains accompany rising seller activity and broader ecosystem adoption.

Profitability: Gross profit reached about $1.16 billion in Q2 2026, up 13% year over year, after a 9% increase for full-year 2025. The trend indicates improving economic contribution from processing, software, and financial services.

Market Expansion: International GPV grew 28% year over year in Q2 2026 while U.S. GPV rose 10%, alongside traction with larger merchants and vertical solutions such as restaurants and banking. These patterns suggest widening geographic and segment reach.